Vyriad
Rochester, US · Delaware corporation
Vyriad is a clinical-stage biotechnology company developing oncolytic virus-based therapies for cancer treatment. It works on engineering viral cancer immunotherapies and GMP virus manufacturing, and has pharma partnerships with companies including Novartis, Regeneron, and Merck KGaA.
Founders & leadership
SJ
Stephen J. Russell, MD, PhDCo-founder
KP
Kah-Whye Peng, PhDCo-founder
SJ
Stephen J. RussellExecutive Chairman and Chief Scientific Officer, Co-founder
KP
Kah-Whye PenginCo-Founder and Chief Technical Officer
LR
Luke RussellinPresident
AS
Alice S. BexoninChief Medical Officer
RA
Roger A. LindahlinChief Financial Officer
JH
James HannonNamed on SEC filing
GN
Glen N. BarberNamed on SEC filing
AC
Ahryon ChoNamed on SEC filing
AK
Andrew KhooNamed on SEC filing
NL
Nathan L. StacyNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$24.4M disclosed across 1 round · 2019
▶$24.4MraisedNov 2019 · 10 investors · BiotechnologyRule 506(b)
▶$24.4MraisedNov 2019 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen J. Russell, MD, PhDExecutive Officer, Director, Promoter
- Kah-Whye Peng, PhDExecutive Officer
- James HannonExecutive Officer
- Glen N. BarberDirector, Promoter
- Ahryon ChoDirector
- Andrew KhooDirector
- Edwin M. Kania, Jr.Director
- Nathan L. StacyDirector
- Alice S. Bexon, MDExecutive Officer
- Offering amount
- $37.8M
- Amount sold
- $24.4M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlapMyriad19 shared keywordsMyriad provides germline and tumor genomic testing across hereditary cancer, prenatal and reproductive health, prostate cancer, and pharmacogenomics for mental health medications. It supplies patients and healthcare providers with genetic screening results and AI-derived insights to inform diagnosis, risk assessment, and treatment decisions.
American Cancer Society (ACS)17 shared keywordsThe American Cancer Society is a nonprofit organization that provides cancer research updates, screening and prevention guidance, and community engagement opportunities. It serves individuals seeking cancer information and those who want to support cancer research and patient advocacy efforts.
Cancerresearchuk16 shared keywordsCancer Research UK funds research across discovery, detection, prevention and treatment of cancer to improve patient outcomes and extend survival. It operates as a research funder and scientific organization serving academic and clinical researchers.
Viridian Therapeutics15 shared keywordsViridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit. The company focuses on clinical development and patient support programs in the biotech sector.
Fred Hutch13 shared keywordsFred Hutch is a cancer research institute that develops biomarkers, therapies, and stem cell products for research and clinical use, and provides data infrastructure and funding to commercialize discoveries into treatments and spinout companies.
Companies competing with Vyriad for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Vyriad do?
- Vyriad is a clinical-stage biotechnology company developing oncolytic virus-based therapies for cancer treatment. It works on engineering viral cancer immunotherapies and GMP virus manufacturing, and has pharma partnerships with companies including Novartis, Regeneron, and Merck KGaA.
- Who founded Vyriad?
- Vyriad was founded by Stephen J. Russell, MD, PhD, Kah-Whye Peng, PhD, Stephen J. Russell, Kah-Whye Peng.
- How much funding has Vyriad raised?
- Vyriad has disclosed $24.4M raised across 1 round.
- Where is Vyriad headquartered?
- Vyriad is headquartered in Rochester, US.